Apeiron RIA’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Apeiron RIA’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,294	Closed	-$606K	–	208
2023 Q3	$606K	Sell	8,294 -4,422	-35%	-$353K	0.21%	84
2023 Q2	$1.06M	Buy	12,716 +429	+3%	+$35.9K	0.36%	50
2023 Q1	$936K	Buy	12,287 +5,761	+88%	+$478K	0.32%	53
2022 Q4	$542K	Buy	6,526 +14	+0.2%	+$1.13K	0.21%	89
2022 Q3	$510K	Buy	+6,512	New	+$549K	0.23%	81

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

CHP

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Apeiron RIA's XBI Position: Q4 2023 in Review

Apeiron RIA sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 8,294 shares — an estimated $606K sold.

Apeiron RIA first reported a position in XBI in Q3 2022 and held it in 5 quarters. The position peaked at $1.06M in Q2 2023. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

Apeiron RIA reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
Apeiron RIA sold 8,294 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $606K.
Apeiron RIA first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and held it in 5 quarters.
Apeiron RIA's State Street SPDR S&P Biotech ETF position peaked at $1.06M in Q2 2023.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on Apeiron RIA's 13F filing for Q4 2023, filed 12 Jan 2024.